PCO-371

PCO‑371 is a non-peptide small molecule that acts as a full agonist of the parathyroid hormone receptor type 1 (PTH1R), a class B G protein-coupled receptor. It was developed by Chugai Pharmaceutical for the potential treatment of hypoparathyroidism and other parathyroid hormone (PTH)-related disorders. Unlike peptide-based therapies such as recombinant human PTH(1–34), PCO‑371 is orally bioavailable and selectively activates human PTHR1 without significant activity at the related type 2 receptor. Preclinical studies demonstrated its ability to increase bone mineral density and restore serum calcium in animal models of osteopenia and hypocalcemia. The drug entered phase I clinical trials in healthy volunteers but development has since been discontinued[3][7][5][6].

Other names

1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione1613373-33-3